Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 9/2009

01-09-2009 | Focussed Research Review

The prevention and treatment of cytomegalovirus infection in haematopoietic stem cell transplantation

Authors: Mark Tuthill, Frederick Chen, Samantha Paston, Hugo De La Peña, Sylvie Rusakiewicz, Alejandro Madrigal

Published in: Cancer Immunology, Immunotherapy | Issue 9/2009

Login to get access

Abstract

Allogeneic haematopoietic stem cell transplantation (HSCT) is an intensive medical treatment involving myeloablative chemo-radiotherapy followed by stem cell rescue using allogeneic haematopoietic stem cells harvested from HLA-matched donors, which is primarily used for the treatment of haematological malignancies. Cytomegalovirus (CMV) infection is one of the major causes of morbidity and death after HSCT. This focused research review highlights the advances made with research into CMV in the HSCT setting. It provides the reader with an overview of current CMV research into the prevention and management of CMV infection.
Literature
1.
Kolb HJ, Schattenberg A, Goldman JM et al (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041–2050PubMed
2.
Gratwohl A, Brand R, Frassoni F et al (2005) Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 36:757–769PubMedCrossRef
3.
Fischer SA (2008) Emerging viruses in transplantation: there is more to infection after transplant than CMV and EBV. Transplantation 86:1327–1339PubMedCrossRef
4.
Alford CA, Stagno S, Pass RF, Britt WJ (1990) Congenital and perinatal cytomegalovirus infections. Rev Infect Dis 12:S745–S753PubMed
5.
Paston SJ, Dodi IA, Madrigal JA (2004) Progress made towards the development of a CMV peptide vaccine. Hum Immunol 65:544–549PubMedCrossRef
6.
Gamadia LE, Remmerswaal EB, Weel JF et al (2003) Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood 101:2686–2692PubMedCrossRef
7.
Casazza JP, Betts MR, Price DA et al (2006) Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. J Exp Med 203:2865–2877PubMedCrossRef
8.
Pourgheysari B, Piper KP, McLarnon A et al (2008) Early reconstitution of effector memory CD4+ CMV-specific T cells protects against CMV reactivation following allogeneic SCT. Bone Marrow Transplant [Epub ahead of print]
9.
Wills MR, Carmichael AJ, Mynard K et al (1996) The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 70:7569–7579PubMed
10.
Riddell SR, Rabin M, Geballe AP et al (1991) Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J Immunol 146:2795–2804PubMed
11.
Solache A, Morgan CL, Dodi AI et al (1999) Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus. J Immunol 163:5512–5518PubMed
12.
Kern F, Surel IP, Faulhaber N et al (1999) Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J Virol 73:8179–8184PubMed
13.
Gyulai Z, Endresz V, Burian K et al (2000) Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs. J Infect Dis 181:1537–1546PubMedCrossRef
14.
Stanley SM, Dodi IA, Evans CR et al (2006) Layer guided-acoustic plate mode biosensors for monitoring MHC-peptide interactions. Analyst 131:892–894PubMedCrossRef
15.
Lacey SF, Villacres MC, La Rosa C et al (2003) Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. Hum Immunol 64:440–452PubMedCrossRef
16.
Höllsberg P (2002) Contribution of HLA class I allele expression to CD8+ T-cell responses against Epstein-Barr virus. Scand J Immunol 55:189–195PubMedCrossRef
17.
Altman JD, Moss PA, Goulder PJ et al (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94–96PubMedCrossRef
18.
Callan MF, Tan L, Annels N et al (1998) Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 187:1395–1402PubMedCrossRef
19.
Chen FE, Aubert G, Travers P et al (2002) HLA tetramers and anti-CMV immune responses: from epitope to immunotherapy. Cytotherapy 4:41–48PubMedCrossRef
20.
Aubert G, Hassan-Walker AF, Madrigal JA et al (2001) Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants. J Infect Dis 184:955–963PubMedCrossRef
21.
Cwynarski K, Ainsworth J, Cobbold M et al (2001) Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 97:1232–1240PubMedCrossRef
22.
Ganepola S, Gentilini C, Hilbers U et al (2007) Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation. Bone Marrow Transplant 39:293–299PubMedCrossRef
23.
Boeckh M, Leisenring W, Riddell SR et al (2003) Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101:407–414PubMedCrossRef
24.
Ozdemir E, Saliba RM, Champlin RE et al (2007) Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 40:125–136PubMedCrossRef
25.
Andrei G, De Clercq E, Snoeck R (2008) Novel inhibitors of human CMV. Curr Opin Investig Drugs 9:32–45
26.
Mercorelli B, Sinigalia E, Loregian A, Palù G (2008) Human cytomegalovirus DNA replication: antiviral targets and drugs. Rev Med Virol 18:177–210PubMedCrossRef
27.
Goodrich JM, Bowden RA, Fisher L et al (1993) Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 118:173–178PubMed
28.
Li CR, Greenberg PD, Gilbert MJ et al (1994) Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83:1971–1979PubMed
29.
Schmidt-Hieber M, Schwarck S, Stroux A et al (2009) Prophylactic i.v. Igs in patients with a high risk for CMV after allo-SCT. Bone Marrow Transplant [Epub ahead of print]
30.
Bale JF Jr, Petheram SJ, Souza IE, Murph JR (1996) Cytomegalovirus reinfection in young children. J Pediatr 128:347–352PubMedCrossRef
31.
Chandler SH, Handsfield HH, McDougall JK (1987) Isolation of multiple strains of cytomegalovirus from women attending a clinic for sexually transmitted disease. J Infect Dis 155:655–660PubMed
32.
Plotkin SA, Smiley ML, Friedman HM et al (1984) Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet 10:528–530CrossRef
33.
Pass RF, Zhang C, Evans A et al (2009) Vaccine prevention of maternal cytomegalovirus infection. NEJM 360:1191–1199PubMedCrossRef
34.
Wloch MK, Smith LR, Boutsaboualoy S et al (2008) Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J Infect Dis 197:1634–1642PubMedCrossRef
35.
Heslop HE, Brenner MK, Rooney C et al (1994) Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts. Hum Gene Ther 5:381–397PubMedCrossRef
36.
Rooney CM, Smith CA, Ng C et al (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345:9–13PubMedCrossRef
37.
Madrigal JA, Travers PJ, Dodi IA (2005) Immunotherapeutic aspects of stem cell transplantation. Hematology 10(Suppl 1):289–292PubMedCrossRef
38.
Dolstra H, Preijers F, Van de Wiel-van Kemenade E et al (1995) Expansion of CD8+ CD57+ T cells after allogeneic BMT is related with a low incidence of relapse and with cytomegalovirus infection. Br J Haematol 90:300–307PubMedCrossRef
39.
Fallen PR, Duarte RF, McGreavey L et al (2003) Identification of non-naïve CD4+CD45RA+ T cell subsets in adult allogeneic haematopoietic cell transplant recipients. Bone Marrow Transplant 32:609–616PubMedCrossRef
40.
Cobbold M, Khan N, Pourgheysari B et al (2005) Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 202:379–386PubMedCrossRef
41.
Micklethwaite KP, Clancy L, Sandher U et al (2008) Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood 112:3974–3981PubMedCrossRef
42.
Myers GD, Krance RA, Weiss H et al (2005) Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant 36:1001–1008PubMedCrossRef
43.
Fujita Y, Rooney CM, Heslop HE (2008) Adoptive cellular immunotherapy for viral diseases. Bone Marrow Transplant 41:193–198PubMedCrossRef
44.
André F, Chaput N, Schartz NE et al (2004) Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol 172:2126–2136PubMed
45.
Segura E, Amigorena S, Thery C (2005) Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses. Blood Cells Mol Dis 35:89–93PubMedCrossRef
46.
De La Peña H, Madrigal JA, Rusakiewicz S et al (2009) Artificial exosomes as tools for basic and clinical immunology. J Immunol Methods [Epub ahead of print]
47.
Babincová M, Altanerová V, Lampert M et al (2000) Site-specific in vivo targeting of magnetoliposomes using externally applied magnetic field. Z Naturforsch [C] 55:278–281
48.
Fortin-Ripoche JP, Martina MS, Gazeau F et al (2006) Magnetic targeting of magnetoliposomes to solid tumors with MR imaging monitoring in mice: feasibility. Radiology 239:415–424PubMedCrossRef
49.
Oelke M, Maus MV, Didiano D et al (2003) Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med 9:619–625PubMedCrossRef
50.
Papanicolaou GA, Latouche JB, Tan C et al (2003) Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele. Blood 102:2498–2505PubMedCrossRef
Metadata
Title
The prevention and treatment of cytomegalovirus infection in haematopoietic stem cell transplantation
Authors
Mark Tuthill
Frederick Chen
Samantha Paston
Hugo De La Peña
Sylvie Rusakiewicz
Alejandro Madrigal
Publication date
01-09-2009
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 9/2009
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-009-0722-7

Other articles of this Issue 9/2009

Cancer Immunology, Immunotherapy 9/2009 Go to the issue

Original Article

BCR/ABL-specific CD8+ T cells can be detected from CML patients, but are only expanded from healthy donors

Review

The immunologic aspects of poxvirus oncolytic therapy

Acknowledgement to Reviewers

Acknowledgement

Original Article

Soluble HLA/peptide monomers cross-linked with co-stimulatory antibodies onto a streptavidin core molecule efficiently stimulate antigen-specific T cell responses

Original Article

−509C>T polymorphism in the TGF-β1 gene promoter, impact on the hepatocellular carcinoma risk in Chinese patients with chronic hepatitis B virus infection

Original Article

Amyloid precursor-like protein 2 association with HLA class I molecules
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits